Category: commentary

analysis, analytics, Aphria, business, Business Analysis, CANADA, canadian, cannabis, Cannin, Cannin Commentary, cbd, commentary, compliance, cultivation, Cultivation & Growing, Dispensaries & Retail, dispensary, earnings, EBITDA, EU, europe, European, export, extraction, Federal, finance, financial, German, government, growing, holdings, import, industry, investing, law, legal, legalization, legalize, legislation, license, marijuana, market, medical, medicine, Operations, product, Product Development, Q2, Quality, quarter, recreational, regulation, regulations, regulatory, report, reporting, results, retail, revenue, second, state, thc, Tilray

Is Tilray Stock a Buy Post Fiscal Q2 Results?

Is Tilray Stock a Buy Post Fiscal Q2 Results?

Canadian cannabis giant Tilray (NASDAQ:TLRY) announced its fiscal second quarter of 2022 results last week. The company reported net revenue of $155 […]